tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Chimerix Hold Rating: Acquisition by Jazz Pharmaceuticals and Uncertain Clinical Prospects Justify Caution
PremiumRatingsChimerix Hold Rating: Acquisition by Jazz Pharmaceuticals and Uncertain Clinical Prospects Justify Caution
4M ago
Chimerix reports Q4 EPS (25c), consensus (28c)
Premium
The Fly
Chimerix reports Q4 EPS (25c), consensus (28c)
4M ago
Chimerix Hold Rating: Financial Constraints and Revised EPS Outlook Influence Cautious Recommendation
Premium
Ratings
Chimerix Hold Rating: Financial Constraints and Revised EPS Outlook Influence Cautious Recommendation
4M ago
Strategic Acquisition and NDA Submission Boost Chimerix’s Market Potential
PremiumRatingsStrategic Acquisition and NDA Submission Boost Chimerix’s Market Potential
5M ago
Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval
Premium
Ratings
Cautious Outlook on Chimerix Amid Acquisition and Uncertainties in Drug Approval
5M ago
Chimerix downgraded to Hold from Buy at Jefferies
Premium
The Fly
Chimerix downgraded to Hold from Buy at Jefferies
5M ago
Chimerix Merges with Jazz Pharmaceuticals in $935M Deal
PremiumCompany AnnouncementsChimerix Merges with Jazz Pharmaceuticals in $935M Deal
5M ago
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash
Premium
The Fly
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash
5M ago
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M
Premium
The Fly
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100